Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alkermes plc (ALKS) SEC filings page on Stock Titan brings together the companys regulatory disclosures from the U.S. Securities and Exchange Commission, offering structured access to its Forms 8-K and other key documents. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline that includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia.
Through its current reports on Form 8-K, Alkermes provides official details on material events. These include financial result announcements, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, along with updates to its annual financial expectations. Such filings often include reconciliations of non-GAAP measures like EBITDA and adjusted EBITDA and discuss revenue contributions from proprietary products and manufacturing and royalty arrangements.
Alkermes also uses Form 8-K to disclose clinical and regulatory milestones, such as positive topline results from phase 2 studies of alixorexton in narcolepsy type 1 and type 2, and to furnish related investor presentations. These documents help readers understand the design, endpoints and topline outcomes of the Vibrance studies and the companys plans for further development.
Another important category of filings relates to transaction agreements and financing. Alkermes has filed a transaction agreement and an amendment describing the terms under which it proposes to acquire Avadel Pharmaceuticals plc, including cash consideration per share and a non-transferable contingent value right linked to a potential regulatory milestone for LUMRYZ. The company has also filed an amended and restated bridge term loan credit agreement, outlining a senior secured bridge term loan facility intended to support financing of the proposed acquisition, along with associated covenants and security arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as earnings updates, clinical trial disclosures, transaction terms and new financing commitments. Real-time updates from EDGAR allow investors to see new ALKS filings as they appear, while structured access to exhibits makes it easier to review detailed agreements, credit facilities and presentation materials.
For those tracking insider and governance information, Alkermes broader SEC reporting framework also encompasses ownership and compensation disclosures in its periodic and proxy filings, which can be accessed alongside 8-Ks. Together, these documents form a detailed record of Alkermes financial condition, strategic transactions, development progress and capital structure.
Alkermes plc is soliciting proxies for its 2026 Annual General Meeting of Shareholders to be held on May 20, 2026, subject to completion. The meeting will consider election of directors, advisory and ratification votes on executive compensation and auditor appointment, renewal of share-allotment and pre-emption authorities, and approval of the amended 2018 Stock Option and Incentive Plan.
Shareholders of record as of March 13, 2026 may vote. The filing highlights 2025 results including $1.48 billion total revenues, $1.2 billion proprietary product net sales, GAAP net income of $242 million, $394 million Adjusted EBITDA, and a year-over-year increase in cash and investments of approximately $495 million. The proxy statement discloses the CEO succession plan (CEO retirement effective July 31, 2026; successor effective August 1, 2026) and notes the completed acquisition of Avadel in February 2026.
Alkermes PLC Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Alkermes PLC common stock and 0% of the class. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report holdings separately.
The amendment is a disclosure of ownership status and reorganization-related reporting changes; it does not show any current beneficial ownership or voting/dispositive power by The Vanguard Group over Alkermes PLC common stock.
Reed Joshua reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that its Senior Vice President and Chief Financial Officer, Joshua Reed, received new equity awards. On March 2, 2026, he was granted 66,430 employee stock options and 30,854 restricted stock units, each RSU representing one ordinary share.
The stock options and RSUs vest in four equal annual installments starting on March 2, 2027, meaning the awards will fully vest over four years if service-based conditions are met. These are non-cash compensation grants and do not represent open-market purchases or sales of Alkermes shares.
POPS RICHARD F reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that Director and CEO Richard F. Pops received a grant of 88,843 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one ordinary share. The entire award is scheduled to vest on December 31, 2026 in connection with the company’s previously announced leadership transition.
Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity awards and a planned share sale. On 3/2/2026, he received an employee stock option for 15,033 shares at an exercise price of $0.00, vesting in four equal annual installments starting 3/2/2027.
He also received a restricted stock unit award for 14,176 units, each representing one ordinary share, vesting in four equal annual installments beginning 3/2/2027. On the same date, he sold 6,890 ordinary shares at $29.29 per share in an open-market transaction under a pre-established Rule 10b5-1 trading plan adopted on 11/7/2025.
Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported both equity awards and a share sale. He received an employee stock option for 66,430 shares and a restricted stock unit award for 30,854 units, each at a grant price of $0.00 per share. Both the option and RSUs vest in four equal annual installments, starting on 3/2/2027. On the same date, he sold 6,000 ordinary shares at $30.00 per share in an open-market transaction effected under a pre-established Rule 10b5-1 trading plan adopted on 11/19/2025, and held 109,769 ordinary shares afterward.
Alkermes plc reported that Executive Vice President and Chief Operating Officer Jackson Blair Curtis received new equity awards. He was granted stock options for 94,900 shares at an exercise price of $0.00 per share and a restricted stock unit award covering 44,078 shares, both held directly.
The stock options vest and become exercisable in four equal annual installments starting on March 2, 2027. The restricted stock units each represent the right to receive one ordinary share and also vest in four equal annual installments beginning on March 2, 2027, tying a significant portion of his compensation to long-term company performance.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported a mix of equity awards, option exercises, and a share sale. He exercised employee stock options for 5,000 ordinary shares at an exercise price of $19.34 per share, then sold 9,000 ordinary shares at a weighted average price of $29.7206 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on 3/14/2025. He also received a new grant of 83,037 employee stock options and a 38,568-share restricted stock unit award, both vesting in four equal annual installments starting 3/2/2027. After these transactions, he directly holds 89,389 ordinary shares of Alkermes.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported a mix of share sales and new equity awards. He sold a total of 4,068 ordinary shares in open-market transactions at $29.29 and $29.76 per share under a pre-arranged Rule 10b5-1 trading plan and held 235,626 shares after the latest sale. He also received a grant of 78,292 stock options and 36,364 restricted stock units, which vest in four equal annual installments starting on March 2, 2027.
Alkermes plc receipt of a Rule 144 notice indicates a proposed sale of 2,034 shares of common stock. The filing lists the issuer as Alkermes plc, the filer name David Gaffin, and a transaction date of 03/03/2026 on NASDAQ.
The filing also lists vesting entries for restricted stock unit and performance share unit awards dated 03/03/2017, 03/03/2018, 05/28/2015, and 10/05/2015, and notes a prior sale by the filer on 03/02/2026.